Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRI NASDAQ:LTRN NASDAQ:TLPH NASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.87-2.4%$0.98$0.55▼$1.19$11.35M0.83196,978 shs162,709 shsLTRNLantern Pharma$3.88-4.7%$2.77$1.11▼$5.74$46.01M2.33256,985 shs132,985 shsTLPHTalphera$0.87+5.2%$0.81$0.38▼$1.57$43.08M0.76138,624 shs233,766 shsTVGNTevogen Bio$10.47-10.3%$7.89$4.14▼$71.00$48.60M0.1435,906 shs23,005 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera+2.70%-10.92%-12.25%+1.92%+36.69%LTRNLantern Pharma+4.90%+5.93%+97.57%+70.29%+20.41%TLPHTalphera+2.68%+3.75%-3.21%+4.17%+61.79%TVGNTevogen Bio+10.09%+18.36%+67.43%+116.91%-82.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.87-2.4%$0.98$0.55▼$1.19$11.35M0.83196,978 shs162,709 shsLTRNLantern Pharma$3.88-4.7%$2.77$1.11▼$5.74$46.01M2.33256,985 shs132,985 shsTLPHTalphera$0.87+5.2%$0.81$0.38▼$1.57$43.08M0.76138,624 shs233,766 shsTVGNTevogen Bio$10.47-10.3%$7.89$4.14▼$71.00$48.60M0.1435,906 shs23,005 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera+2.70%-10.92%-12.25%+1.92%+36.69%LTRNLantern Pharma+4.90%+5.93%+97.57%+70.29%+20.41%TLPHTalphera+2.68%+3.75%-3.21%+4.17%+61.79%TVGNTevogen Bio+10.09%+18.36%+67.43%+116.91%-82.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera 2.00HoldN/AN/ALTRNLantern Pharma 1.00SellN/AN/ATLPHTalphera 2.25Hold$3.00243.49% UpsideTVGNTevogen Bio 1.50Reduce$100.00855.11% UpsideCurrent Analyst Ratings BreakdownLatest BFRI, TVGN, LTRN, and TLPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026TLPHTalphera Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/5/2026TLPHTalphera HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.006/1/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026LTRNLantern Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026LTRNLantern Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/30/2026TLPHTalphera Westpark CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.004/27/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026TLPHTalphera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026TVGNTevogen Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$41.71M0.27N/AN/A$0.90 per share0.96LTRNLantern PharmaN/AN/AN/AN/A$0.58 per shareN/ATLPHTalphera$30K1,510.98N/AN/A$0.37 per share2.36TVGNTevogen BioN/AN/AN/AN/A($211.84) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$10.54M-$0.97N/A14.42N/A-25.66%-515.34%-53.91%8/12/2026 (Estimated)LTRNLantern Pharma-$17.12M-$1.45N/AN/AN/AN/A-198.34%-129.08%8/12/2026 (Estimated)TLPHTalphera-$14.29M-$0.31N/AN/AN/AN/A-92.98%-53.22%8/13/2026 (Estimated)TVGNTevogen Bio-$26.27M-$4.61N/AN/AN/AN/AN/A-472.77%8/13/2026 (Estimated)Latest BFRI, TVGN, LTRN, and TLPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026LTRNLantern Pharma-$0.36-$0.30+$0.06-$0.30N/AN/A5/15/2026Q1 2026TVGNTevogen Bio-$2.64-$1.61+$1.03-$1.61N/AN/A5/14/2026Q1 2026BFRIBiofrontera-$0.1150-$0.41-$0.2950-$0.41$10.25 million$10.08 million5/13/2026Q1 2026TLPHTalphera-$0.07-$0.04+$0.03-$0.04N/AN/A3/30/2026Q4 2025LTRNLantern Pharma-$0.46-$0.36+$0.10-$0.36N/AN/A3/23/2026Q4 2025 & Investor DayTLPHTalphera-$0.0750-$0.06+$0.0150-$0.06$0.58 millionN/A3/19/2026Q4 2025BFRIBiofrontera$0.29$0.50+$0.21$0.47$16.15 million$17.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofrontera0.781.201.09LTRNLantern PharmaN/A1.871.87TLPHTalpheraN/A5.305.30TVGNTevogen BioN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%LTRNLantern Pharma28.62%TLPHTalphera37.67%TVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipBFRIBiofrontera4.80%LTRNLantern Pharma8.50%TLPHTalphera3.50%TVGNTevogen Bio70.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera7012.80 million12.19 millionNo DataLTRNLantern Pharma2011.31 million10.34 millionOptionableTLPHTalphera1951.90 million50.08 millionOptionableTVGNTevogen Bio34.16 million1.23 millionN/ABFRI, TVGN, LTRN, and TLPH HeadlinesRecent News About These CompaniesTevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services InitiativeJune 10 at 1:47 PM | finanznachrichten.deTevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO AcquisitionsJune 9 at 3:51 PM | quiverquant.comQTevogen Announces Formation of a Healthcare Services InitiativeJune 9 at 3:30 PM | globenewswire.comTevogen Bio (NASDAQ:TVGN) Trading 6.2% Higher - Should You Buy?June 6, 2026 | americanbankingnews.comTevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual RevenueMay 28, 2026 | finanznachrichten.deTevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ...May 28, 2026 | enidnews.comETevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual RevenueMay 28, 2026 | globenewswire.comTevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services ...May 21, 2026 | caledonianrecord.comCTevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare TransactionMay 21, 2026 | quiverquant.comQTevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services OrganizationMay 21, 2026 | globenewswire.comTevogen Bio Holdings Inc. Reports Significant Operational Improvements and Strategic Growth InitiativesMay 18, 2026 | quiverquant.comQLetter to Shareholders from CEO Dr. Ryan SaadiMay 18, 2026 | globenewswire.comTevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...May 12, 2026 | caledonianrecord.comCTevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLPMay 12, 2026 | quiverquant.comQTevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market CloseMay 12, 2026 | globenewswire.comTevogen (TVGN) Soars 11% as Firm Gears Up for AI Training CommercializationMay 5, 2026 | finance.yahoo.comTevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application PortalApril 27, 2026 | finance.yahoo.comTevogen.AI Nears Completion of PredicTcellâ„¢ Training; Initiates Commercial Readiness and Debuts Internal Application PortalApril 27, 2026 | globenewswire.comTevogen Bio krijgt melding van Nasdaq wegens niet-naleving beursregelsApril 23, 2026 | nl.investing.comTevogen Bio Faces Nasdaq Market Value Compliance ChallengesApril 22, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBFRI, TVGN, LTRN, and TLPH Company DescriptionsBiofrontera NASDAQ:BFRI$0.87 -0.02 (-2.39%) Closing price 04:00 PM EasternExtended Trading$0.87 +0.01 (+0.68%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Lantern Pharma NASDAQ:LTRN$3.88 -0.19 (-4.67%) Closing price 04:00 PM EasternExtended Trading$3.92 +0.04 (+1.11%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Talphera NASDAQ:TLPH$0.87 +0.04 (+5.23%) Closing price 04:00 PM EasternExtended Trading$0.87 0.00 (-0.05%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.Tevogen Bio NASDAQ:TVGN$10.47 -1.20 (-10.28%) Closing price 04:00 PM EasternExtended Trading$9.64 -0.83 (-7.93%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
